U.S., Jan. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07330245) titled 'Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.' on Dec. 19, 2025.
Brief Summary: This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5
Study Start Date: Dec. 31, 2025
Study Type: OBSERVATIONAL
Condition:
Lupus Erythematosus, Systemic
Intervention:
BIOLOGICAL: Anifrolumab
anifrolumab - fully human monoclonal antibody target type I INF
Recruitment Status: RECRUITING
Sponsor: AstraZeneca
Published by HT Digital Content Services with permission from Heal...